Jack Bendheim Sells 7,040 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Key Points

• CEO Jack Bendheim sold 7,040 shares on April 16 at an average price of $54.64 for $384,665.60, reducing his direct stake to 117,000 shares (a 5.68% decrease); the sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• Bendheim has repeatedly sold shares since February (multiple 7,040-share transactions plus larger disposals such as 10,560 shares on March 18), signaling ongoing insider selling activity over the past months.
• PAHC traded down about 2.1% to $53.88 that day; the company has a $2.18 billion market cap, recently beat quarterly EPS estimates ($0.87 vs. $0.69), set FY2026 guidance of 2.930–3.100 EPS, and pays a $0.12 quarterly dividend (≈0.9% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the company's stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $54.64, for a total transaction of $384,665.60. Following the sale, the chief executive officer directly owned 117,000 shares in the company, valued at approximately $6,392,880. The trade was a 5.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $59.08, for a total transaction of $415,923.20.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.

Phibro Animal Health Trading Down 2.1%

Phibro Animal Health stock traded down $1.13 during trading on Thursday, reaching $53.88. The company had a trading volume of 281,231 shares, compared to its average volume of 311,222. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $60.08. The stock's 50 day moving average price is $53.29 and its two-hundred day moving average price is $44.96. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 0.84 and a beta of 0.69. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million for the quarter, compared to analysts' expectations of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were given a dividend of $0.12 per share. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health's dividend payout ratio is currently 21.33%.

Analysts Set New Price Targets

PAHC has been the subject of a number of research analyst reports. Zacks Research raised shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Citigroup initiated coverage on shares of Phibro Animal Health in a report on Wednesday. They issued a "neutral" rating and a $62.00 price target for the company. Weiss Ratings reissued a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Phibro Animal Health presently has an average rating of "Hold" and a consensus target price of $42.40.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company's stock worth $57,519,000 after buying an additional 13,884 shares during the last quarter. State Street Corp increased its holdings in Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company's stock worth $35,204,000 after buying an additional 48,243 shares during the last quarter. Millennium Management LLC increased its holdings in Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company's stock worth $23,959,000 after buying an additional 626,492 shares during the last quarter. Geode Capital Management LLC increased its holdings in Phibro Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company's stock worth $21,265,000 after buying an additional 21,951 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Phibro Animal Health by 1.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company's stock worth $18,394,000 after buying an additional 6,826 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.